1.
Efficacy and safety of strontium ranelate in the treatment of knee osteoarthritis: results of a double-blind, randomised placebo-controlled trial
by Reginster, Jean-Yves
Annals of the rheumatic diseases, 2013-02, Vol.72 (2), p.179-186
2.
The epidemiology of ankylosing spondylitis and the commencement of anti-TNF therapy in daily rheumatology practice
by Cruyssen, Bert Vander
Annals of the rheumatic diseases, 2007-08, Vol.66 (8), p.1072-1077
3.
Nationwide prevalence of rheumatoid arthritis and penetration of disease-modifying drugs in Sweden
by Neovius, Martin
Annals of the rheumatic diseases, 2011-04, Vol.70 (4), p.624-629
4.
Longitudinal analysis of citrullinated protein/peptide antibodies (anti-CP) during 5 year follow up in early rheumatoid arthritis: anti-CP status predicts worse disease activity an...
by Rönnelid, J
Annals of the rheumatic diseases, 2005-12, Vol.64 (12), p.1744-1749
5.
Genetic markers for the efficacy of tumour necrosis factor blocking therapy in rheumatoid arthritis
by Padyukov, L
Annals of the rheumatic diseases, 2003-06, Vol.62 (6), p.526-529
6.
Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists
by Askling, J
Annals of the rheumatic diseases, 2005-10, Vol.64 (10), p.1421-1426
7.
Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists
by Askling, J
Annals of the rheumatic diseases, 2005-10, Vol.64 (10), p.1414-1420
8.
Biomarkers and personalised medicine in rheumatoid arthritis: a proposal for interactions between academia, industry and regulatory bodies
by Miossec, P
Annals of the Rheumatic Diseases, 2011-10, Vol.70 (10), p.1713-1718
9.
A phase III randomised, double-blind, parallel-group study comparing SB4 with etanercept reference product in patients with active rheumatoid arthritis despite methotrexate therapy
by Emery, Paul Paul
Annals of the rheumatic diseases, 2015-07-06, Vol.76 (1), p.51-57
10.
A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with...
by Park, Won
Annals of the rheumatic diseases, 2013-10, Vol.72 (10), p.1605-1612
11.
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update
by Smolen, Josef S
Annals of the rheumatic diseases, 2014-03, Vol.73 (3), p.492-509
12.
Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4,...
by Fleischmann, Roy, Prof
The Lancet (British edition), 2017, Vol.390 (10093), p.457-468
13.
Autoantibody formation in patients with rheumatoid arthritis treated with anti-TNFα
by Eriksson, C
Annals of the rheumatic diseases, 2005-03, Vol.64 (3), p.403-407
14.
Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial
by McInnes, Iain B, Prof
The Lancet (British edition), 2015, Vol.386 (9999), p.1137-1146
15.
A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexat...
by Yoo, Dae Hyun
Annals of the rheumatic diseases, 2013-10, Vol.72 (10), p.1613-1620
16.
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs
by Smolen, Josef S
Annals of the Rheumatic Diseases, 2010-06, Vol.69 (6), p.964-975
17.
Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2013 update of the EULAR recommendations for the management of rheumatoid...
by Nam, Jackie L
Annals of the rheumatic diseases, 2014-03, Vol.73 (3), p.516-528
18.
A randomised, double-blind, phase III study comparing SB2, an infliximab biosimilar, to the infliximab reference product Remicade in patients with moderate to severe rheumatoid art...
by Choe, Jung-Yoon Jung-Yoon
Annals of the rheumatic diseases, 2015-08-28, Vol.76 (1), p.58-64
19.
Safety of synthetic and biological DMARDs: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis
by Ramiro, Sofia
Annals of the rheumatic diseases, 2014-03, Vol.73 (3), p.529-535
20.
Key findings towards optimising adalimumab treatment: the concentration-effect curve
by Pouw, Mieke F
Annals of the rheumatic diseases, 2015, Vol.74 (3), p.513-518
